{"id":"sglt2-inhibitors","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Genital mycotic infections"},{"rate":"3–10","effect":"Urinary tract infections"},{"rate":"5–10","effect":"Polyuria"},{"rate":"<1","effect":"Diabetic ketoacidosis"},{"rate":"2–5","effect":"Hypotension"},{"rate":"<1","effect":"Acute kidney injury"}]},"_chembl":{"chemblId":"CHEMBL5760702","moleculeType":null,"molecularWeight":"276.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting SGLT2 in the proximal tubule of the nephron, these drugs reduce the reabsorption of filtered glucose, leading to increased urinary glucose loss and lower blood glucose levels. This mechanism is insulin-independent and also promotes natriuresis and modest weight loss. Beyond glycemic control, SGLT2 inhibitors have demonstrated cardiovascular and renal protective effects, including reduced heart failure hospitalization and slowing of diabetic kidney disease progression.","oneSentence":"SGLT2 inhibitors block the sodium-glucose cotransporter 2 in the kidney, preventing reabsorption of glucose and increasing urinary glucose excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:47.546Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"},{"name":"Type 1 diabetes (in combination with insulin)"}]},"trialDetails":[{"nctId":"NCT07488689","phase":"PHASE3","title":"Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-07","conditions":"Septic Shock","enrollment":568},{"nctId":"NCT07022379","phase":"","title":"Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program","status":"COMPLETED","sponsor":"Satelia","startDate":"2021-01-01","conditions":"Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Reduced Ejection Fraction","enrollment":13660},{"nctId":"NCT07491042","phase":"NA","title":"Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.","status":"RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2026-04-01","conditions":"End Stage Chronic Renal Failure","enrollment":38},{"nctId":"NCT04128995","phase":"PHASE4","title":"Surgical or Medical Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-15","conditions":"Diabetes Mellitus, Type 2, Pediatric Obesity, Bariatric Surgery Candidate","enrollment":88},{"nctId":"NCT06217302","phase":"PHASE3","title":"Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease","status":"RECRUITING","sponsor":"Alessandro Doria","startDate":"2024-10-31","conditions":"Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1","enrollment":150},{"nctId":"NCT07157475","phase":"","title":"Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors","status":"RECRUITING","sponsor":"Wroclaw Medical University","startDate":"2025-07-01","conditions":"Peripheral Arterial Disease(PAD)","enrollment":300},{"nctId":"NCT07482943","phase":"PHASE4","title":"The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-04","conditions":"Fontan, Heart Failure, Dapagliflozin","enrollment":30},{"nctId":"NCT07482020","phase":"PHASE2","title":"SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03-01","conditions":"Atrial Fibrillation (AF), Hypertension","enrollment":66},{"nctId":"NCT05013112","phase":"NA","title":"Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-01-01","conditions":"Kidney Transplantation, Metabolic Disorder, Metformin","enrollment":105},{"nctId":"NCT06905405","phase":"","title":"The Use of Advanced Imaging in HFpEF","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2025-08-05","conditions":"Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":40},{"nctId":"NCT07478575","phase":"","title":"Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2019-01-01","conditions":"Heart Failure, Anemia, Renal Insufficiency","enrollment":85},{"nctId":"NCT07120828","phase":"PHASE4","title":"The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity","status":"COMPLETED","sponsor":"Erbil Polytechnic University","startDate":"2025-07-15","conditions":"Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)","enrollment":260},{"nctId":"NCT07472920","phase":"NA","title":"Empagliflozin Adjunctive Therapy in Bipolar Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-03-09","conditions":"Bipolar Disorder, Bipolar Depression, Insulin Resistance","enrollment":20},{"nctId":"NCT05309785","phase":"PHASE4","title":"Safety and Efficacy of Canagliflozin in Advanced CKD","status":"ACTIVE_NOT_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-11-24","conditions":"ESRD, CKD Stage 4, CKD Stage 5","enrollment":35},{"nctId":"NCT06913647","phase":"PHASE2","title":"Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-02-01","conditions":"ESRD, CKD (Chronic Kidney Disease) Stage 5D","enrollment":30},{"nctId":"NCT05986136","phase":"PHASE2, PHASE3","title":"Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2023-08-20","conditions":"Inflammatory Bowel Diseases","enrollment":50},{"nctId":"NCT03878706","phase":"","title":"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","status":"RECRUITING","sponsor":"University of Athens","startDate":"2017-11-03","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT07053319","phase":"PHASE1","title":"SGLT2i, Pioglitazone, and Ketone Production in T2D","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-07-20","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT05182658","phase":"PHASE3","title":"Empagliflozin in Hypertrophic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-06-01","conditions":"Hypertrophic Cardiomyopathy, Heart Failure","enrollment":250},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT06055452","phase":"PHASE4","title":"Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-01-19","conditions":"Pre-Heart Failure, Hypertension","enrollment":120},{"nctId":"NCT07450417","phase":"","title":"Effect of Early Empagliflozin Initiation in Cardiogenic Shock.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-03-10","conditions":"Cardiogenic Shock","enrollment":418},{"nctId":"NCT03982381","phase":"PHASE4","title":"SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2019-09-05","conditions":"Type 2 Diabetes","enrollment":2067},{"nctId":"NCT07063316","phase":"","title":"SGLT2 Inhibitors and Renal Anemia in Japan: RWD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-07-23","conditions":"Chronic Kidney Disease","enrollment":15000},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT07441187","phase":"","title":"Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-20","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":300},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07025629","phase":"PHASE3","title":"Dapagliflozin for Cardio-renal Protection After ICU Discharge","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-02","conditions":"Heart Failure and Chronic Kidney Disease Post-ICU","enrollment":600},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT05890131","phase":"NA","title":"Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Morten Schou","startDate":"2023-05-03","conditions":"Heart Failure","enrollment":5996},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT06430684","phase":"EARLY_PHASE1","title":"Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2024-08-23","conditions":"Chronic Kidney Diseases, Pediatric Kidney Disease","enrollment":40},{"nctId":"NCT07421518","phase":"PHASE2","title":"Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2026-06","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":75},{"nctId":"NCT07044700","phase":"","title":"Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2028-01-31","conditions":"Heart Failure of Reduced Ejection Fraction (HFrEF)","enrollment":5000},{"nctId":"NCT05741658","phase":"PHASE4","title":"The Fontan Dapagliflozin Pilot Study","status":"ENROLLING_BY_INVITATION","sponsor":"Johns Hopkins University","startDate":"2023-11-08","conditions":"Heart Failure","enrollment":29},{"nctId":"NCT07417306","phase":"PHASE3","title":"A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2026-03-27","conditions":"Type 2 Diabetes","enrollment":912},{"nctId":"NCT06526195","phase":"NA","title":"Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure","status":"RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2024-12-13","conditions":"Heart Failure, Heart Diseases, Cardiovascular Diseases","enrollment":850},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT06932081","phase":"","title":"Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-01-01","conditions":"Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle","enrollment":400},{"nctId":"NCT05944432","phase":"NA","title":"CGM Use in Adults With Type 2 Diabetes on Basal Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Diabetes Care","startDate":"2023-07-14","conditions":"Diabetes Mellitus, Type 2","enrollment":470},{"nctId":"NCT07405944","phase":"PHASE4","title":"Vericiguat and Reverse Remodeling Indices in Heart Failure","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-11-01","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure","enrollment":60},{"nctId":"NCT05139914","phase":"PHASE4","title":"Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-05-31","conditions":"Diabetes Mellitus, Type 2, Endothelial Dysfunction","enrollment":4},{"nctId":"NCT07323524","phase":"PHASE4","title":"Dapagliflozin in Active Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-01","conditions":"Lupus Nephritis (LN)","enrollment":33},{"nctId":"NCT07392788","phase":"NA","title":"Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2026-04","conditions":"Acute Heart Failure (AHF)","enrollment":144},{"nctId":"NCT06229678","phase":"EARLY_PHASE1","title":"Ketones, SGLT2, HFrEF","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01-25","conditions":"Type2diabetes, Heart Failure With Reduced Ejection Fraction","enrollment":71},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07379788","phase":"","title":"ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling","status":"RECRUITING","sponsor":"Rehab Werida","startDate":"2025-12-25","conditions":"Heart Failure","enrollment":180},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT06221969","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-01-16","conditions":"Type 2 Diabetes","enrollment":1000},{"nctId":"NCT07367555","phase":"PHASE1","title":"Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients","status":"COMPLETED","sponsor":"Ariba Shafiq","startDate":"2024-10-01","conditions":"Diabete Mellitus","enrollment":360},{"nctId":"NCT07360457","phase":"","title":"GLP1 Analogues and the Risk of Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2026-02-01","conditions":"Osteoarthritis","enrollment":390},{"nctId":"NCT06065540","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":2734},{"nctId":"NCT07355023","phase":"NA","title":"AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","status":"RECRUITING","sponsor":"Tri-Service General Hospital","startDate":"2026-01-01","conditions":"Left Ventricular (LV) Systolic Dysfunction","enrollment":5000},{"nctId":"NCT07214818","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2025-11-15","conditions":"Nephrotic Syndrome","enrollment":75},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07355088","phase":"","title":"Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Xinjiang Medical University","startDate":"2026-01-01","conditions":"Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":600},{"nctId":"NCT03867487","phase":"PHASE2","title":"SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease","status":"NOT_YET_RECRUITING","sponsor":"Justin Ryder","startDate":"2027-05-01","conditions":"Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD","enrollment":40},{"nctId":"NCT06149793","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2024-01-08","conditions":"Cystic Fibrosis-related Diabetes, Cystic Fibrosis","enrollment":8},{"nctId":"NCT07351643","phase":"PHASE4","title":"CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-02-25","conditions":"ACS (Acute Coronary Syndrome), SGLT2 Inhibitors","enrollment":110},{"nctId":"NCT07351864","phase":"PHASE4","title":"Finerenone Plus SGLT2 Inhibitors in Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-18","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT07348718","phase":"","title":"Rubix LS Diabetic Kidney Disease (DKD) Registry Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rubix LS","startDate":"2025-12-15","conditions":"Diabetic Kidney Disease (DKD)","enrollment":2000},{"nctId":"NCT07348484","phase":"","title":"Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2026-01","conditions":"Chronic Kidney Disease","enrollment":300},{"nctId":"NCT07342764","phase":"PHASE4","title":"Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2026-04","conditions":"Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":120},{"nctId":"NCT07344922","phase":"PHASE3","title":"SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-09-01","conditions":"Chronic Kidney Disease, Anemia, Cardiovascular Calcification","enrollment":100},{"nctId":"NCT07332156","phase":"","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)","enrollment":21692},{"nctId":"NCT06887062","phase":"PHASE2","title":"Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-21","conditions":"Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis","enrollment":60},{"nctId":"NCT07334145","phase":"","title":"Effect of SGLT2 Inhibitors on Anemic CKD Patients","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-01-01","conditions":"Anemia in CKD Patients","enrollment":60},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT07338331","phase":"NA","title":"Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Galala University","startDate":"2023-04-04","conditions":"Diabete Type 2, Non Alcoholic Fatty Liver","enrollment":80},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT01512849","phase":"PHASE1","title":"A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01387737","phase":"PHASE3","title":"Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1299},{"nctId":"NCT01022112","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":383},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT01413204","phase":"PHASE3","title":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-07","conditions":"Type 2 Diabetes Mellitus","enrollment":272},{"nctId":"NCT07322237","phase":"PHASE4","title":"DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors","enrollment":400},{"nctId":"NCT06858436","phase":"PHASE4","title":"SGLT2 Inhibitor Utilization Re-perfusion Therapy","status":"NOT_YET_RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2026-01-23","conditions":"Acute Ischemic Stroke From Large Vessel Occlusion","enrollment":150},{"nctId":"NCT06812429","phase":"EARLY_PHASE1","title":"Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2024-05-08","conditions":"Inflammation","enrollment":6},{"nctId":"NCT05313529","phase":"NA","title":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-08","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":396},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT05831085","phase":"NA","title":"Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease","status":"RECRUITING","sponsor":"Duk-Woo Park, MD","startDate":"2024-06-14","conditions":"Coronary Artery Stenosis","enrollment":1500},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07311109","phase":"NA","title":"A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-15","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":150},{"nctId":"NCT06285760","phase":"","title":"Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)","status":"RECRUITING","sponsor":"Puerta de Hierro University Hospital","startDate":"2024-03-01","conditions":"Heart Failure, Persistent Congestion","enrollment":64},{"nctId":"NCT07172971","phase":"PHASE1","title":"Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Larry W. Markham","startDate":"2026-02-01","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":10},{"nctId":"NCT07302464","phase":"","title":"Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-10-01","conditions":"Sodium Glucose Co-Transporter 2 Inhibitors, Estimated Glomerular Filtration Rate, Diabetes","enrollment":60},{"nctId":"NCT06297603","phase":"PHASE3","title":"Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-03-15","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT06609356","phase":"EARLY_PHASE1","title":"Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-07-03","conditions":"Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes","enrollment":27},{"nctId":"NCT07295522","phase":"PHASE4","title":"Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2026-01-08","conditions":"Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":368},{"nctId":"NCT05991284","phase":"PHASE4","title":"Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2024-02-29","conditions":"Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation","enrollment":84},{"nctId":"NCT07294495","phase":"NA","title":"Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR","status":"NOT_YET_RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-07","conditions":"HCM - Hypertrophic Cardiomyopathy","enrollment":150},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT02891954","phase":"PHASE1","title":"Genetics of Response to Canagliflozin","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2016-09","conditions":"Diabetes Mellitus, Type 2","enrollment":700},{"nctId":"NCT07174687","phase":"PHASE2","title":"SGLT2 Inhibitors in Geographic Atrophy","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-12-02","conditions":"Retinal Degeneration, Retinal Diseases, Eye Diseases","enrollment":70},{"nctId":"NCT07292909","phase":"PHASE4","title":"Effect of Empagliflozin on Inflammation","status":"RECRUITING","sponsor":"Hotel Dieu de France Hospital","startDate":"2025-09-01","conditions":"CAD - Coronary Artery Disease, Inflamation, PCI","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6624,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Canagliflozin tablets or Glucophage","Empagliflozin","Canagliflozin"],"phase":"marketed","status":"active","brandName":"SGLT2 Inhibitors","genericName":"SGLT2 Inhibitors","companyName":"Pharmaceuticals and Medical Devices Agency, Japan","companyId":"pharmaceuticals-and-medical-devices-agency-japan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SGLT2 inhibitors block the sodium-glucose cotransporter 2 in the kidney, preventing reabsorption of glucose and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}